KUALA LUMPUR: Duopharma Biotech Bhd said earnings climbed in the first quarter of stronger demand for healthcare products.
Net profit rose 30% to RM17.6mil from RM13.56mil a year ago. Revenue improved 5% to RM166mil.
The company, which has a deal to supply Sputnik V vaccine to the government, is also proposing to issue bonus shares on the basis of one free share for every three shares held at a date to be determined later.
"Pending the execution and signing of definitive supply agreements and conditional approval by the Drug Control Authority, the management of vaccine supply is expected to contribute positively to the future earnings of Duopharma Group for the financial nyear ending Dec 31, 2021," it said.